From: Association of MTHFR gene polymorphisms with breast cancer survival
Age at diagnosis (mean ± SD; n = 248) | 55.0 ± 13.9 |
Body mass index (mean ± SD; n = 248) | 29.1 ± 8.0 |
 | N (%) |
Race/Ethnicity | Â |
   African-American | 143 (58) |
   Caucasian | 105 (42) |
Menopausal status at diagnosis | Â |
   Pre-menopausal | 64 (31) |
   Post-menopausal | 141 (69) |
Alcohol consumption | Â |
   No | 93 (41) |
   Yes | 133 (59) |
Survival | Â |
   Alive | 189 (76) |
   Deceased2 | 59 (24) |
Tumor histology | Â |
   Ductal | 189 (76) |
   Lobular | 34 (14) |
   Others | 25 (10) |
Node status | Â |
   Negative | 144 (63) |
   Positive | 84 (37) |
Stage at diagnosis (TNM) | Â |
   ≤ Stage I | 66 (29) |
   Stage II | 118 (52) |
   ≥ Stage III | 44 (19) |
Chemotherapy | Â |
   No | 99 (43) |
   Yes3 | 132 (57) |
Neoadjuvant therapy | Â |
   No | 178 (77) |
   Yes | 53 (23) |
Estrogen receptor-α |  |
   Negative | 102 (41) |
   Positive | 145 (59) |
HER2/neu | Â |
   Low to weak | 154 (62) |
   Moderate to strong | 93 (38) |